Smith Neale, Smith Anne, Wang Alice, Shaw Kaitlyn, Groeneweg Gabriella, Goldman Ran D, Wilkinson Bryan, Jimenez Ricardo, Mwai Leah, Carleton Bruce
Centre for Clinical Epidemiology and Evaluation, Vancouver Coastal Health Research Institute, University of British Columbia, Vancouver, British Columbia.
Division of Translational Therapeutics, Department of Pediatrics, University of British Columbia, Vancouver, British Columbia.
Paediatr Child Health. 2017 Jul;22(4):190-194. doi: 10.1093/pch/pxx047. Epub 2017 May 5.
Administration of oral corticosteroids at the onset of an upper respiratory tract infection (URTI) can be effective in the management of acute asthma exacerbations in children. This study was designed to identify barriers to parent-initiated implementation of clinical practice guideline-recommended use of oral corticosteroids for prophylaxis against severe asthma exacerbations in children.
Twenty-seven children who presented to BC Children's Hospital with URTI-induced asthma exacerbations were recruited. Parents received a filled prescription for a course of oral corticosteroids to be used at the earliest onset of their child's next URTI. Each family was contacted monthly over a 1-year period to inquire about URTI events, asthma symptoms, medication use and health care utilization. Focus groups were held with family physicians, paediatricians and parents; transcripts were analyzed qualitatively to identify key themes.
Incidence of URTI events among participants was high (85%). Uptake of study medication was low; 44% used the medication as directed at their first URTI event. Eleven per cent of the patients who used the study medication also visited the emergency department for an exacerbation. Focus groups identified four main barriers to the effective use of parent-initiated oral corticosteroids: physician resistance and conflicting messages from providers; parent uncertainty about oral corticosteroids; multiple caregivers and relative ease of access to an emergency department.
We have identified key barriers to the effective use of parent-administered oral corticosteroids as an asthma management strategy and gained important insights regarding the research that is required to enhance the applicability of the strategy.
在上呼吸道感染(URTI)发作时给予口服皮质类固醇可有效治疗儿童急性哮喘加重。本研究旨在确定家长主动实施临床实践指南推荐的口服皮质类固醇预防儿童严重哮喘加重的使用方法时所面临的障碍。
招募了27名因URTI诱发哮喘加重而到卑诗省儿童医院就诊的儿童。家长收到一份口服皮质类固醇疗程的已填好的处方,以便在孩子下次URTI最早发作时使用。在1年的时间里,每月与每个家庭联系,询问URTI事件、哮喘症状、药物使用和医疗保健利用情况。与家庭医生、儿科医生和家长进行了焦点小组讨论;对文字记录进行定性分析以确定关键主题。
参与者中URTI事件的发生率很高(%)。研究药物的使用率很低;44%的人在首次发生URTI事件时按指示使用了药物。使用研究药物的患者中有11%也因病情加重而去了急诊科。焦点小组确定了家长主动使用口服皮质类固醇的有效使用的四个主要障碍:医生的抵触和提供者相互矛盾的信息;家长对口服皮质类固醇的不确定性;多个照顾者以及相对容易进入急诊科。
我们确定了家长给予口服皮质类固醇作为哮喘管理策略有效使用的关键障碍,并获得了关于提高该策略适用性所需研究的重要见解。 (注:原文中“85%”和“11%”处表述不完整,可能存在信息缺失)